Screening for prostatakreft i Norge

Forfattere

  • Sophie D. Fosså
  • P. Å. Høisæter

DOI:

https://doi.org/10.5324/nje.v11i2.549

Sammendrag

 

ENGLISH SUMMARY

Fosså SD, Høisæter PÅ.

 

Screening for prostate cancer in Norway. Nor J Epidemiol 2001; 11 (2): 147-152.

Background

 

 

Results

 

 

Conclusion

 

 

. Population-based PSA screening can not be recommended in Norway. PSA-based opportunistic

screening should be substantially reduced. If an asymptomatic man persistently requires PSA

testing, the responsible doctor has to inform him about the potential disadvantages as well as the potential

benefits associated with opportunistic screening, diagnosis and treatment of prostate cancer. PSAscreening

should be considered as a public health care strategy, depending on the results of the ERPCS.

. The rate of opportunistic screening in Norway in elderly men was about 7% in 1999 but is

increasing, with significant differences between the counties. The current health care strategy is to limit

opportunistic screening to a minimum, as the effectiveness of this task is unproven. Reduction of mortality

can only be achieved by the early diagnosis and treatment of “clinically important” prostate

cancer. The identification of these cases remains problematic in clinical routine. Data from the Cancer

Registry of Norway, and knowledge about prostate cancer tumour biology and epidemiology leave

doubt whether the aim of the ERPCS can be reached in 2008: The Norwegian Urological Cancer Group

has therefore not recommended Norway's participation in the ERPCS.

. PSA-based opportunistic screening for prostate cancer is increasing throughout the

world, and also in Norway. The mortality reducing effectiveness of population-based PSA screening

has, however, so far not been proven and it is currently addressed by a European randomised trial

(ERPCS). This trial aims to demonstrate a 20% reduction of the prostate cancer-related mortality rate in

the year 2008 in men who have had regular PSA analysis and, if possible, curatively intended treatment

of a newly diagnosed prostate cancer.

Downloads

Download data is not yet available.

Nedlastinger

Publisert

2009-11-07

Hvordan referere

Fosså, S. D., & Høisæter, P. Å. (2009). Screening for prostatakreft i Norge. Norsk Epidemiologi, 11(2). https://doi.org/10.5324/nje.v11i2.549

Utgave

Vol 11 Nr 2 (2001): The Cancer Registry of Norway, 50 years / Kreftregisteret 50 år (Volume 11, No. 2,125-204 ).

Seksjon

Articles

Lisens

Norsk Epidemiologi licenses all content of the journal under a Creative Commons Attribution (CC-BY) licence. This means, among other things, that anyone is free to copy and distribute the content, as long as they give proper credit to the author(s) and the journal. For further information, see Creative Commons website for human readable or lawyer readable versions.

Authors who publish with this journal agree to the following terms:

1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.

2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.

3. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).